| 1. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1116,
1997,
Page 2-2
&NA;,
Preview
|
PDF (1221KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 2. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1116,
1997,
Page 3-3
&NA;,
Preview
|
PDF (1068KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 3. |
Is an atovaquone/proguanil donation programme appropriate in Africa? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1116,
1997,
Page 4-4
&NA;,
Preview
|
PDF (1181KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 4. |
DOTS cost effective for TB |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1116,
1997,
Page 5-5
&NA;,
Preview
|
PDF (1153KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 5. |
Trial of protein C in meningococcal-induced purpura needed |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1116,
1997,
Page 6-6
&NA;,
Preview
|
PDF (1075KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 6. |
Rituximab plus CHOP: a new approach for non-Hodgkin's lymphoma? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1116,
1997,
Page 7-8
Robert Carlson,
Preview
|
PDF (2196KB)
|
|
摘要:
A 100% response rate was achieved by combining a novel monoclonal antibody, rituximab [‘Rituxan’, IDEC-C2B8; IDEC Pharmaceuticals], with standard chemotherapy in a phase II clinical trial involving patients with refractory low-grade and follicular B-cell non-Hodgkin's lymphoma. The scientific rationale for combination therapy, and these positive study results were presented to delegates attending the Chemotherapy Foundation Symposium XV [New York, US; November 1997].
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 7. |
Bivalirudinvsheparin for angioplasty |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1116,
1997,
Page 8-8
&NA;,
Preview
|
PDF (1119KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 8. |
Abecarnil relieves anxiety … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1116,
1997,
Page 9-9
&NA;,
Preview
|
PDF (1074KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 9. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1116,
1997,
Page 10-10
&NA;,
Preview
|
PDF (1119KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 10. |
HOT action promises multiple benefits in hypertension |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1116,
1997,
Page 11-12
Larry Prescott,
Preview
|
PDF (2295KB)
|
|
摘要:
The Hypertension Optimal Treatment (HOT) study reached maturity at the end of August 1997. The currently available 3-year data strongly suggest that target BPs can be obtained in a high percentage of patients through careful, aggressive antihypertensive treatment. Also, initial subgroup analyses indicate that renal function can be improved, and the patient's well-being can be maintained, when strictly normotensive levels are reached. These findings were presented during the 70th Scientific Sessions of the American Heart Association [Orlando, US; November 1997].
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
首页
